(Q42599146)

3 November 2017

0 references

The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1316063

12 September 2022

author name string

E. Rizk

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1316063

12 September 2022

language of work or name

English

0 references

publication date

1 April 1992

1 reference

3 November 2017

6 April 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1316063

full work available at URL

12 September 2022

https://api.elsevier.com/content/article/PII:0002934392903256?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

https://api.elsevier.com/content/article/PII:0002934392903256?httpAccept=text/plain

4 December 2023

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

American Journal of Medicine

4 December 2023

published in

1 reference

3 November 2017

volume

92

1 reference

3 November 2017

issue

4A

1 reference

3 November 2017

page(s)

130S-135S

1 reference

The evolution of fluorinated quinolones: pharmacology, microbiological activity, clinical uses, and toxicities

3 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

The adverse effects of fluoroquinolones

4 December 2023

3

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Adverse effects of the fluoroquinolones.

4 December 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Crystalluria and ciprofloxacin, influence of urinary pH and hydration

4 December 2023

5

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

In-vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin

4 December 2023

6

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

In vitro and in vivo activity of NY-198, a new difluorinated quinolone

4 December 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Comparative in vitro activity of lomefloxacin, a difluoro-quinolone

4 December 2023

8

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone.

4 December 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Mechanism of action of lomefloxacin

4 December 2023

10

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils.

4 December 2023

12

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Bactericidal activity of lomefloxacin SC 47111 (NY-198) and ciprofloxacin against selected pathogens.

4 December 2023

13

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Effect of enoxacin on theophylline neurotoxicity

4 December 2023

14

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum

4 December 2023

15

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Effect of norfloxacin on theophylline metabolism

4 December 2023

17

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline

4 December 2023

18

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Effect of lomefloxacin on theophylline pharmacokinetics

4 December 2023

19

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid

4 December 2023

20

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Kinetic interaction between theophylline and a newly developed quinolone, NY-198

4 December 2023

21

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline

4 December 2023

22

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Influence of lomefloxacin on the pharmacokinetics of theophylline

4 December 2023

23

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man

4 December 2023

24

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Lack of interaction between lomefloxacin and caffeine in normal volunteers

4 December 2023

25

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Reduced enteral absorption of ciprofloxacin in the presence of antacids

4 December 2023

26

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Inhibition of enoxacin absorption by antacids or ranitidine

4 December 2023

29

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Sucralfate reduces the gastrointestinal absorption of norfloxacin

4 December 2023

30

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Sucralfate significantly reduces ciprofloxacin concentrations in serum

4 December 2023

32

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

Assessment and validation of animal models to evaluate topical effects of substances on gastrointestinal mucosa

4 December 2023

33

1 reference

https://api.crossref.org/works/10.1016/0002-9343(92)90325-6

4 December 2023

Identifiers

1 reference

3 November 2017

1 reference